Hepatitis C/HCV



Patient is a Null Responder Patient is a Relapser

Current Weight:______Date: _____

Height (pediatrics):_____Date:____

Genotype: □ la □ lb □ 2 □ 3 □ 4 □ 5 □ 6

☐ Positive for Q80K Polymorphism

Prescriber's Signature Required:

Primary Diagnosis Code:____

Prescription/Pharmacy Intake Form

Rx Phone: **718-323-8377**

Ship to □ Specialty Care Center □ Patient's Home **Provider Representative** Phone **Date Needed** ☐ Prescriber's Office □ Other PATIENT INFORMATION DOB: _____ Male Female Patient Name: _____ Address:___ Zip Code: _____ City: State: _____ Phone # (Evening):_____ Phone # (Daytime):_____ E-mail Address: _ Insurance Provider (**Please include copy of front and back of card**): Phone #:_____ ID #:_ ______ Policy/Group #:____ Name of Insured:____ Employer:____ Other:____ ☐ Patient is Eligible for Medicare Relationship to Patient: ☐ Self ☐ No Prescription Card: Yes Policy/Group #:_ Carrier:___ **CLINICAL ASSESSMENT** PRESCRIPTION INFORMATION Medication Directions/Freq | Qty | Refills ☐ Patient is Naive

☐ 90mg/400mg tablets

☐ Moderiba[™] Dose Pack ☐ Ribasphere® Ribapak®

☐ 12.5/75/50mg and 250mg tablets

☐ Ribasphere®

☐ 200 mg capsules

☐ 150 mg capsules

☐400 mg tablets

□200 mg capsules

Rx FAX: **718-323-9377**

Harvoni®

Olysio™

Sovaldi®

Victrelis®

Viekira Pak™

☐ Moderiba™

 \square 200 mg tablets

Initial Viral Load:IU/mL Date of Initial Viral Load: Previous Treatment: Yes, with	□ Moderiba™ Dose Pack □ Ribasphere® Ribapak® □ 600 mg/day = 200-400: 200 mg AM/400 mg PM □ 800 mg/day = 400-400: 400 mg AM/400 mg PM □ 1,000 mg/day = 600-400: 600 mg AM/400 mg PM □ 1,200 mg/day = 600-600: 600 mg AM/600 mg PM
Fibrosis Score: Cirrhosis	Ribavirin □ 200 mg tablets □ 200 mg capsules
☐ Decompensate Other Health Conditions:	190 10 5 1 11 - 1 11
Allergies:	PegIntron®
Concomitant Medications:	
	☐ Granix™ ☐ Neupogen® ☐ Promacta® ☐
PRESCRIBER INFORMATION	N
Prescriber's Name:	Practice/Facility Name:
Address:	
City: S	tate: Zip Code:
Phone #:	Fax: Best Time to Call:
State License #: DEA #	NPI#: Medicaid UPIN #:
In order for a brand name product to be dispe	nsed, the prescriber must handwrite "Brand Necessary" or "Brand Medically
Necessary," or your state specific required language to prohibit substitution:	
I certify that the above therapy is medically no	ecessary and that the information above is accurate to the best of my knowledge.

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws.

IMPORTANT WARNING: This is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employer or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.

Drug names are the property of their respective owners.

Secondary Signature Optional:

Date:

Date: